Resmed INC Form 4 insider transactions

ResMed Director Desney Tan received an award of 1,073 Restricted Stock Units, increasing his beneficial ownership to 6,002 shares.

ResMed Inc. Director Harjit Gill was granted 1,073 Restricted Stock Units, increasing beneficial ownership to 10,940 shares.

ResMed Inc. Director Karen Drexler received an award of 1,073 Restricted Stock Units, increasing her beneficial ownership.

ResMed Inc. director Carol Burt received an award of 1,073 Restricted Stock Units, vesting by November 2026.

ResMed Inc. Director Ronald R. Taylor received an award of 1,073 Restricted Stock Units, increasing his beneficial ownership to 24,771 shares.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, acquired 2,710 shares of common stock after performance metrics for restricted stock units were met.

ResMed's Chairman and CEO, Michael J. Farrell, reported the vesting of 13,551 performance-based restricted stock units and the subsequent disposition of 7,297 shares for tax withholding.

ResMed Director Christopher DelOrefice was granted 1,073 Restricted Stock Units, increasing his beneficial ownership to 2,423 shares.

ResMed Inc. director Jan De Witte was granted 1,073 Restricted Stock Units, increasing his beneficial ownership.

ResMed Inc. Director Peter C. Farrell reported the acquisition of 536 Restricted Stock Units, vesting by November 2026, under a pre-planned transaction.

Richard Sulpizio has ceased serving as a director of ResMed Inc. following the company's 2025 annual meeting of stockholders.

ResMed Director Peter C. Farrell exercised 11,442 stock options and subsequently sold 7,314 shares to cover tax obligations.

ResMed Inc. Director Harjit Gill disposed of 38.209 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

ResMed Inc. Director Peter C. Farrell reported the sale of 2,000 common shares and a tax-related disposition of 162.953 shares.

ResMed Inc.'s Chairman and CEO, Michael J. Farrell, disposed of 7,896.567 shares of common stock on November 11, 2025, to cover tax obligations related to the vesting of Restricted Stock Units.

ResMed Director Jan De Witte reported the sale of 487 common shares and the disposition of 76.449 shares for tax withholding related to RSU vesting.

ResMed Global General Counsel Michael J. Rider reported multiple dispositions of common stock to cover tax obligations upon RSU vesting, alongside an ESPP purchase.

ResMed Chairman and CEO Michael J. Farrell exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

ResMed CEO Michael J. Farrell exercised stock options and sold 8,009 shares of common stock for a significant profit, as part of a pre-arranged Rule 10b5-1 trading plan.

ResMed's Chief Financial Officer, Brett Sandercock, executed a pre-planned transaction involving the exercise of stock options and subsequent sale of common stock on October 1, 2025.

Michael J. Rider, ResMed's Global General Counsel, reported the sale of 100 shares of common stock on October 1, 2025, executed under a Rule 10b5-1 trading plan.

ResMed CEO Michael J. Farrell exercised stock options and subsequently sold 8,009 shares of common stock under a pre-arranged 10b5-1 plan.

ResMed Inc. Director Nicole Mowad-Nassar was granted 241 restricted stock units, scheduled to vest one year from the grant date.

ResMed Inc.'s Chief Financial Officer, Brett Sandercock, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

ResMed's Chief Product Officer, Justin Leong, acquired 5,462 shares of common stock through the vesting of performance-based restricted stock units.

ResMed's Chief Financial Officer, Brett Sandercock, acquired 5,462 shares of common stock through the earning of performance-based restricted stock units.

ResMed's CEO, Michael J. Farrell, acquired 12,289 shares of common stock through the vesting of performance-based restricted stock units.

ResMed Inc. Director John Hernandez exercised stock options and subsequently sold a portion of his common stock holdings.

ResMed's Global General Counsel, Michael J. Rider, acquired 2,941 shares of common stock through the vesting of performance-based restricted stock units.